Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Blocking the Spread of Deadly Brain Tumors

By Drug Discovery Trends Editor | April 20, 2009

Researchers at the Translational Genomics Research Institute (TGen) may have found a way to stop the often-rapid spread of deadly brain tumors.

A gene with the playful-sounding name NHERF-1 may be a serious target for drugs that could prevent malignant tumors from rapidly multiplying and invading other parts of the brain, according to a study.

Cancer cell movement and rapid division are key characteristics of malignant brain tumors known as glioblastoma multiforme, or GBM.

Dr. Michael Berens, Director of TGen’s Cancer and Cell Biology Division, said the recent findings are a major step toward devising a treatment for GBM, which because of its ability to rapidly grow within the brain often means patients have little time to survive.

‘Controlling the actions of tumor cells by regulating NHERF-1 implicates it as a possible therapeutic target for treating brain cancer,’ said Dr. Kerri Kislin, a scientist in TGen’s Cancer and Cell Biology Division.

‘Our findings suggest a novel mechanism defining NHERF-1 as a molecular switch that regulates the GBM tumor cell’s ability to migrate or divide,’ said Dr. Kislin, the scientific paper’s lead author.

Dr. Berens, the paper’s senior author, said the advances made by TGen not only confirm NHERF-1 as a gene associated with brain tumors, but also pinpoint it as a possible cause for their rapid growth and spread of GBM.

‘Dr. Kislin’s work has meant a fast maturation of NHERF-1 from a candidate gene associated with glioma invasion to positioning it as having a verified role in contributing to the malignant behavior of the disease,’ Dr. Berens said.

Glioblastomas are essentially incurable tumors, in part, because there is no way to remove them surgically and ensure that all of the invading tumor cells are gone, even when surgery is followed by radiation treatments and conventional anti-cancer drugs.

‘A chemotherapeutic treatment which targets these migrating cells would therefore have significant ramifications on patient survival,’ said Dr. Jennifer M. Eschbacher, a Neuropathology Fellow at Barrow Neurological Institute, who examined tumors for the study.

‘As a pathologist, I examined expression of NHERF-1 under the microscope in tumor sections, including both invading edges of tumor and cellular tumor cores. We found NHERF-1 to be robustly expressed by invading tumors cells, when compared to tumor cores, suggesting that this factor plays a significant role in tumor invasion,’ Dr. Eschbacher said.

In the study, depletion of NHERF-1 stopped the migration of glioma – brain cancer – cells, she said. ‘These results suggest that NHERF-1 plays an important role in tumor biology, and that targeted inhibition of this factor may have significant effects on patient treatment and survival.’

Release Date: April 17, 2009
Source: The Translational Genomics Research Institute


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

DNA Script SYNTAX
DNA Script raises $165M Series C for DNA printing platform
DNA Script SYNTAX
DNA Script launches a benchtop DNA printer
DNA
Unraveling the promise of genetics for treating progressive illness 
Alzheimer's disease
How to build a foundation for the next phase of Alzheimer’s disease research

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50